Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Problems in Pediatric Drug Therapy PDF full book. Access full book title Problems in Pediatric Drug Therapy by Louis A. Pagliaro. Download full books in PDF and EPUB format.
Author: Louis A. Pagliaro Publisher: American Pharmaceutical Association ISBN: Category : Medical Languages : en Pages : 1174
Book Description
This reference volume addresses distinct pharmaceutical care issues for all paediatric age ranges, from neonatal to adolescent. This third edition of the text includes two new chapters covering: paediatric pharmocokinetics and abusable psychtropic drugs.
Author: Louis A. Pagliaro Publisher: American Pharmaceutical Association ISBN: Category : Medical Languages : en Pages : 1174
Book Description
This reference volume addresses distinct pharmaceutical care issues for all paediatric age ranges, from neonatal to adolescent. This third edition of the text includes two new chapters covering: paediatric pharmocokinetics and abusable psychtropic drugs.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309225493 Category : Medical Languages : en Pages : 432
Book Description
The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.
Author: Andrew E. Mulberg Publisher: John Wiley & Sons ISBN: 1118312058 Category : Medical Languages : en Pages : 782
Book Description
Most medicines have never been adequately tested for safety and efficacy in pediatric populations and preterm, infants and children are particularly vulnerable to adverse drug reactions. Pediatric Drug Development: Concepts and Applications, Second Edition, addresses the unique challenges in conducting effective drug research and development in pediatric populations. This new edition covers the legal and ethical issues of consent and assent, the additional legal and safety protections for children, and the appropriate methods of surveillance and assessment for children of varying ages and maturity, particularly for patient reported outcomes. It includes new developments in biomarkers and surrogate endpoints, developmental pharmacology and other novel aspects of global pediatric drug development. It also encompasses the new regulatory initiatives across EU, US and ROW designed to encourage improved access to safe and effective medicines for children globally. From an international team of expert contributors Pediatric Drug Development: Concepts and Applications is the practical guide to all aspects of the research and development of safe and effective medicines for children.
Author: Jacob V. Aranda Publisher: Elsevier Health Sciences ISBN: 0323552919 Category : Medical Languages : en Pages :
Book Description
Dr. Aranda is an top expert in the area of pharmacology in the pediatric population. His issue has knowledgeable authors presenting clinical reviews on a wide variety of topics, from "hot areas " of drug therapy to drug abuse in children as well as current areas of debate in neonatal drug therapy. Articles are devoted to the following topics: New and Current Drug Therapies For Asthma In Children; Psychopharmacology Of Bipolar Disorders in Children and Adolescents; Designer Drug Abuse in School Children; Dietary Supplements in Children; Anticoagulant Therapies in Children; New Antimicrobials for Gram-Positive Infections in Children; Probiotics in Newborns And Children; Anticonvulsant Therapies in Newborns and Children; Immunomodulator Drug Therapies in Inflammatory Bowel Diseases in Children; Non-Steroidal Anti-Inflammatory Drugs in Newborns and Children; Metformin Use in Pre-Diabetic Children and Adolescents; Problems in Drug Dosing of Obese Children; Inhaled Drugs and Systemic Steroids for Bronchopulmonary Dysplasia; Antifungal Drugs in Newborns and Children; Antiviral Drugs In Newborns and Children; and Development of Drug Therapies for Newborns and Children. Readers will come away with the latest clinical information to help inform them when diagnosing and prescribing for children.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309183642 Category : Medical Languages : en Pages : 135
Book Description
The Institute of Medicine's (IOM's) Roundtable on Research and Development of Drugs, Biologics, and Medical Devices evolved from the Forum on Drug Development, which was established in 1986. Sponsor representatives and IOM determined the importance of maintaining a neutral setting for discussions regarding long-term and politically sensitive issues justified the need to revise and enhance past efforts. The new Roundtable is intended to be a mechanism by which a broad group of experts from the public* and private sectors can be convened to conduct a dialogue and exchange information related to the development of drugs, biologics, and medical devices. Members have expertise in clinical medicine, pediatrics, clinical pharmacology, health policy, health insurance, industrial management, and product development; and they represent interests that address all facets of public policy issues. From time to time, the Roundtable requests that a workshop be conducted for the purpose of exploring a specific topic in detail and obtaining the views of additional experts. The first workshop for the Roundtable was held on April 14 and 15, 1998, and was entitled Assuring Data Quality and Validity in Clinical Trials for Regulatory Decision Making. The summary on that workshop is available from IOM. This workshop summary covers the second workshop, which was held on May 24 and 25, 1999, and which was aimed at facilitating the development and proper use of drugs, biologics, and medical devices for infants and children. It explores the scientific underpinnings and clinical needs, as well as the regulatory, legal, and ethical issues, raised by this area of research and development.
Author: Robert D. Friedberg Publisher: Springer Nature ISBN: 3030216837 Category : Psychology Languages : en Pages : 461
Book Description
This handbook offers a comprehensive review of cognitive behavioral therapy (CBT) for working in integrated pediatric behavioral health care settings. It provides research findings, explanations of theoretical concepts and principles, and descriptions of therapeutic procedures as well as case studies from across broad conceptual areas. Chapters discuss the value of integrated care, diversity issues, ethical considerations, and the necessary adaptations. In addition, chapters address specific types of pediatric conditions and patients, such as the implementation of CBT with patients with gastrointestinal complaints, enuresis, encopresis, cancer, headaches, epilepsy, sleep problems, diabetes, and asthma. The handbook concludes with important directions in research and practice, including training and financial considerations.Topics featured in this handbook include: Emotional regulation and pediatric behavioral health problems. Dialectical Behavior Therapy (DBT) for pediatric medical conditions. Pharmacological interventions and the combined use of CBT and medication. CBT in pediatric patients with chronic pain. CBT for pediatric obesity. CBT-informed treatments and approaches for transgender and gender expansive youth. Medical non-compliance and non-adherence associated with CBT. Training issues in pediatric psychology. The Handbook of Cognitive Behavioral Therapy for Pediatric Medical Conditions is an essential resource for researchers and graduate students as well as clinicians, related therapists, and professionals in clinical child and school psychology, pediatrics, social work, developmental psychology, behavioral therapy/rehabilitation, child and adolescent psychiatry, nursing, and special education.
Author: Klaus Rose Publisher: Karger Medical and Scientific Publishers ISBN: 3805593627 Category : Medical Languages : en Pages : 240
Book Description
Children in the developed world have never enjoyed better medical care: mortality has decreased and many fatal diseases of the past can today be prevented or even cured. However, the current practice of pharmacotherapy in children does not reflect existing scientific knowledge and has come under scrutiny by paediatricians, pharmacists and regulatory authorities. In order to advance the development of medicines tailored to paediatric needs, US and EU legislators have taken action, and the WHO has initiated a global paediatric campaign. This book gives an overview over the worldwide activities that increasingly include children in the development of new medicines. Triggered by both a better understanding of how the child's body develops as well as recent legislation in the USA and in Europe, this comprises dosing, ethics, age-appropriate pharmaceutical forms and clinical trials, to name just a few aspects.A wide spectrum of readers will profit from this book, including paediatricians, pharmacists, general practitioners and health care professionals involved in child care and paediatric research, clinical trial personnel, patient advocacy groups, ethics committees, politicians, parents and interested lay persons.
Author: Sharna Olfman Publisher: Bloomsbury Publishing USA ISBN: Category : Psychology Languages : en Pages : 321
Book Description
This book exposes the skyrocketing rate of antipsychotic drug prescriptions for children, identifies grave dangers when children's mental health care is driven by market forces, describes effective therapeutic care for children typically prescribed antipsychotics, and explains how to navigate a drug-fueled mental health system. Since 2001, there has been a dramatic increase in the use of antipsychotics to treat children for an ever-expanding list of symptoms. The prescription rate for toddlers, preschoolers, and middle-class children has doubled, while the prescribing rate for low-income children covered by Medicaid has quadrupled. In a majority of cases, these drugs are neither FDA-approved nor justified by research for the children's conditions. This book examines the reasons behind the explosion of antipsychotic drug prescriptions for children, spotlighting the historical and cultural factors as well as the role of the pharmaceutical industry in this trend; and discusses the ethical and legal responsibilities and ramifications for non-MDs—psychologists in particular—who work with children treated with antipsychotics. Contributors explain how the pharmaceutical industry has inserted itself into every step of medical education, rendering objectivity in the scientific understanding, use, and approvals of such drugs impossible. The text describes the relentless marketing behind the drug sales, even going as far as to provide coloring and picture books for children related to the drug at issue. Valuable information about legal recourse that families and therapists can take when their children or patients have been harmed by antipsychotic drugs and alternative approaches to working with children with emotional and behavioral challenges is also provided.
Author: Cynthia A Connolly Publisher: Rutgers University Press ISBN: 0813575230 Category : Health & Fitness Languages : en Pages : 339
Book Description
Winner of the 2018 Arthur J. Viseltear Award from the Medical Care Section of the American Public Health Association Children and Drug Safety traces the development, use, and marketing of drugs for children in the twentieth century, a history that sits at the interface of the state, business, health care providers, parents, and children. This book illuminates the historical dimension of a clinical and policy issue with great contemporary significance—many of the drugs administered to children today have never been tested for safety and efficacy in the pediatric population. Each chapter of Children and Drug Safety engages with major turning points in pediatric drug development; themes of children’s risk, rights, protection and the evolving context of childhood; child-rearing; and family life in ways freighted with nuances of race, class, and gender. Cynthia A. Connolly charts the numerous attempts by Congress, the Food and Drug Administration, the American Academy of Pediatrics, and leading pediatric pharmacologists, scientists, clinicians, and parents to address a situation that all found untenable. Open access edition funded by the National Endowment for the Humanities. The text of this book is licensed under a Creative Commons Attribution NonCommercial-NoDerivatives 4.0 International License: https://creativecommons.org/licenses/by-nc-nd/4.0/
Author: Louis A. Pagliaro
Author: Louis A. Pagliaro
Author: Institute of Medicine
Author: Andrew E. Mulberg
Author: Jacob V. Aranda
Author: Institute of Medicine
Author: Robert D. Friedberg
Author: Klaus Rose
Author: Sharna Olfman
Author: United States. Food and Drug Administration. Bureau of Drugs
Author: Cynthia A Connolly